Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.76 |
| ▸ | POLH | Q9Y253 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | TNKS | O95271 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PARP1 | P09874 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817277 | 0.87 | CYP3A4 (1.00) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL30591245 | 0.87 | CYP3A4 (1.00) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL15850944 | 0.84 | POLH (0.77) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL14145325 | 0.83 | CYP3A4 (0.76) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL20602392 | 0.83 | CYP3A4 (0.76) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL25449242 | 0.82 | AR (0.73) | MAPTCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL31303695 | 0.80 | CYP3A4 (0.67) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL9138573 | 0.80 | CYP3A4 (0.67) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL10026574 | 0.80 | POLH (0.74) | MAPTPOLHCYP3A4KDM4EMEN1 | |
| SCHEMBL5981301 | 0.79 | ABCB1 (0.73) | MAPTPOLHCYP3A4KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MAPT 2788/4885POLH 1682/4885CYP3A4 718/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MAPT 2788/4885POLH 1682/4885CYP3A4 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.